Ariad Pharm Inc (ARIA) 10.12 $ARIA Biotech Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ariad Pharm Inc (ARIA) 10.12 $ARIA

Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)

ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09), ARIA: 10.12 (-0.07)

Shares of ARIA Up 29.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 31, 1:12AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 1 month, Ariad Pharmaceuticals has returned 29.32% as of today's recent price of $10.43.
ARIA: 10.12 (-0.07)

After Yesterday's Rally of 1.52% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 30, 4:11PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.27 to a high of $10.45. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $10.39 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 10.12 (-0.07)

ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug Administration
BusinessWire - Tue Aug 30, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA). ARIAD is seeking U.S. marketing approval of brigatinib for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib. The Company is seeking accelerated approval for brigatinib from the FDA and has requested a priority review of the application, which, if granted, would allow for approval of brigatinib eight months after the NDA submission, as opposed to 12 months for a standard review.
ARIA: 10.12 (-0.07)

ARIAD to Present at the Morgan Stanley Global Healthcare Conference
BusinessWire - Mon Aug 29, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company's business on Monday, September 12, 2016 at 2:50 p.m. (ET).
ARIA: 10.12 (-0.07), MS: 31.89 (-0.02)

SmarTrend Watching for Potential Pullback in Shares of Ariad Pharmaceuticals After 1.32% Gain
Comtex SmarTrend(R) - Wed Aug 24, 2:35PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $10.51 to a high of $10.85. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $10.82 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 10.12 (-0.07)

Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 30.1% (ARIA)
Comtex SmarTrend(R) - Tue Aug 23, 1:16PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 1 month, Ariad Pharmaceuticals has returned 30.07% as of today's recent price of $10.49.
ARIA: 10.12 (-0.07)

32.2% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA)
Comtex SmarTrend(R) - Tue Aug 16, 12:44AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 3 weeks, Ariad Pharmaceuticals has returned 32.18% as of today's recent price of $10.66.
ARIA: 10.12 (-0.07)

Look for Shares of Ariad Pharmaceuticals to Potentially Pullback after Yesterday's 2.30% Rise
Comtex SmarTrend(R) - Tue Aug 09, 3:40PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $9.92 to a high of $10.35. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $10.18 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 10.12 (-0.07)

Ariad Pharmaceuticals Up 24.5% Since SmarTrend Uptrend Call (ARIA)
Comtex SmarTrend(R) - Mon Aug 08, 1:46PM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on July 22nd, 2016 at $8.07. In approximately 2 weeks, Ariad Pharmaceuticals has returned 24.49% as of today's recent price of $10.04.
ARIA: 10.12 (-0.07)

Potash Corporation of Saskatchewan trade offers a 38% return in 134 days, or find similar option trades on American Airlines, Wynn Resorts, Monsanto Company, and Ariad Pharmaceuticals
PR Newswire - Fri Aug 05, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, ARIA, MON, POT, and WYNN.
MON: 107.44 (+0.53), POT: 17.99 (+0.18), WYNN: 92.38 (-0.79), AAL: 36.53 (+0.29), ARIA: 10.12 (-0.07)

4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 313.59 (+7.56), BMRN: 95.73 (+0.54), GILD: 76.89 (-0.53), AMGN: 169.77 (-0.36), ABBV: 64.12 (+0.09), ARIA: 10.12 (-0.07), AEGN: 19.01 (+0.47)

PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 10.12 (-0.07), PDLI: 2.99 (+0.02)

Bank of America trade offers a 9% return in 204 days, or find similar option trades on Ariad Pharmaceuticals, US Steel, CyberArk Software, and Abbott Laboratories
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, ARIA, BAC, CYBR, and X.
ABT: 42.09 (-0.21), CYBR: 55.38 (+1.75), BAC: 16.00 (+0.02), ARIA: 10.12 (-0.07), X: 18.90 (-0.43)

ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 8:23AM CDT
ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ZTS: 51.26 (+0.15), INCY: 82.02 (+1.21), ARIA: 10.12 (-0.07), NKTR: 18.45 (+0.34)

Ariad Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 10.45%
Comtex SmarTrend(R) - Thu Jul 28, 1:22PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.80 to a high of $9.38. Yesterday, the shares gained 10.5%, which took the trading range above the 3-day high of $8.45 on volume of 9.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 10.12 (-0.07)

ARIAD (ARIA) Swings to Earnings in Q2, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:12AM CDT
ARIAD (ARIA) posted better-than-expected results in Q2 with revenues benefiting from a one-time impact related to revenue recognition in France.
ARIA: 10.12 (-0.07)

ARIAD Reports Second Quarter and First Half 2016 Financial Results
BusinessWire - Thu Jul 28, 6:34AM CDT
--~U.S. product revenue of $32.6 million for Q2 2016, representing 50% growth from prior year
ARIA: 10.12 (-0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 177

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 94

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 98

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 185

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 188

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 64

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 152

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 17

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 116

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 35

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating the Rising Tide of AI-Driven Cyber Threats

Updated Category News Views 118

The Evolving Landscape of Cyber Threats In today's world, artificial intelligence is rapidly changing the nature of cyber threats. Recent studies reveal that a significant number of companies have encountered AI-driven cyberattacks, highlighting a critical gap in their defense strategies. Despite this alarming trend, many organizations are yet to fully embrace AI in their...

Continue Reading
Insight into the Bullish Movements Surrounding DPZ Stock

Updated Category News Views 58

Understanding the Options Dynamics for Domino's Pizza Investors are expressing a clear bullish sentiment towards Domino's Pizza as evident from the recent options market activities. Analyzing the options history for Domino's Pizza (DPZ), we found a total of 10 significant trades. These trades reveal that approximately 50% of traders leaned towards bullish strategies while...

Continue Reading
PDD Holdings Faces Legal Challenges Over Securities Violations

Updated Category News Views 230

PDD Holdings Faces Legal Challenges Over Securities Violations PDD Holdings, Inc. is currently facing a major class action lawsuit. This legal action stems from accusations that the company misled investors about potential compromises to its applications, raising serious concerns about user privacy, particularly regarding unauthorized access to private messages. Details...

Continue Reading
Significant Shareholder Announcement for Kenmare Resources

Updated Category News Views 98

Major Holdings Notification for Kenmare Resources Plc Understanding the dynamics of major shareholdings is essential for investors and stakeholders alike. Kenmare Resources Plc has recently updated the market regarding key holdings that affect its share structure. The notification process is transparent, with clear communication ensuring that all relevant details are...

Continue Reading
Exploring High-Yield Dividend Stocks for Income Investors

Updated Category News Views 65

Dive into Dividend Investing Dividend investing is often overlooked, especially in an era dominated by the latest advancements in technology and artificial intelligence. While the allure of tech growth may be tempting, savvy investors understand the enduring value of reliable income-generating stocks. The world of dividend stocks is vast, and their potential for...

Continue Reading